IP Library Granted Patent US 6,943,242
Granted Patent B2
US 6,943,242 · App. 10/140,545 · Granted Sep 13, 2005

Design of artificial genes for use as controls in gene expression analysis systems

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,943,242
App. No.
10/140,545
Granted
Sep 13, 2005
Kind
B2
Abstract

Method of producing controls for use in gene expression analysis systems such as macroarrays, real-time PCR, northern blots, SAGE and microarrays. The controls are generated either from near-random sequence of DNA, or from inter- or intragenic regions of a genome. Ten specific control sequences are also disclosed. Also presented are methods of using these controls, including as negative controls, positive controls, and as calibrators of a gene expression analysis system.

Claims (13)

1. A control for use in a gene expression analysis system comprising:

a known amount of at least one DNA target generated from at least one intergenic or intronic region of genomic DNA from a known sequence; or

a known amount of at least one spike mRNA generated from DNA generated from said at least one intergenic or intronic region of genomic DNA from a known sequence, wherein

(a) said at least one DNA is selected from the group consisting of

(i) SEQ ID No: 1; and

(ii) a complete complement of the sequence set forth in (i); or

(b) said at least one mRNA is transcribed from the group consisting of

(i) SEQ ID No: 11; and

(ii) a complete complement of the sequence set forth in (i).

2. The control of claim 1 wherein, said at least one DNA target or spike mRNA do not hybridize at high stringency with any DNA or mRNA from a source other than said at least one intergenic or intronic region of genomic DNA.

3. The control of claim 1 , wherein said at least one DNA target or spike mRNA is formulated at selected concentrations and ratios.

4. The control of claim 1 , wherein said at least one DNA target is addressably disposed upon a substrate.

5. The control of claim 1 , wherein said at least one spike mRNA is detectably labeled.

Assignments (3)
CHANGE OF NAME Recorded Apr 20, 2006
From: AMERSHAM BIOSCIENCES (SV) CORP
To: GE HEALTHCARE (SV) CORP.
Reel/Frame 017492/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2005
From: AMERSHAM BIOSCIENCES CORP..
To: AMERSHAM BIOSCIENCES (SV) CORP
Reel/Frame 015815/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2002
From: SAMARTZIDOU, HRISSI; TURNER, LEAH; DANIEL, STEVEN; HOUTS, THOMAS
To: AMERSHAM BIOSCIENCES CORP.
Reel/Frame 013106/0100 →